Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Income Taxes |
|
| Schedule of loss from continuing operation before income tax |
The loss from operations before income tax for the years ended December 31, 2025 and 2024 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2025 |
|
|
2024 |
|
| Pre-Tax Loss |
|
|
|
|
|
|
|
|
| Domestic |
|
$ |
(24,910 |
) |
|
$ |
(22,450 |
) |
Foreign
|
|
|
(1,699 |
) |
|
|
(1,037 |
) |
| Total |
|
$ |
(26,609 |
) |
|
$ |
(23,487 |
) |
|
| Schedule of components of income tax provision |
The components of the income tax provision as for the year ended December 31, 2025 and 2024 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2025 |
|
|
2024 |
|
| Income Tax Provision |
|
|
|
|
|
|
|
|
| Federal |
|
$ |
— |
|
|
$ |
— |
|
| Foreign |
|
|
— |
|
|
|
— |
|
| State |
|
|
— |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
| Total |
|
$ |
— |
|
|
$ |
2 |
|
|
| The components of deferred income assets and liabilities as of December 31, 2025 and 2024 are as follows (in thousands): |
The components of deferred income assets and liabilities as of December 31, 2025 and 2024 are as follows (in thousands):
| |
|
|
|
|
|
|
|
| |
|
December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Deferred Tax: |
|
|
|
|
|
|
|
|
| Accruals and reserves |
|
$ |
493 |
|
|
$ |
523 |
|
| Capitalized R&E §174 |
|
|
— |
|
|
|
6,722 |
|
| Lease ROU |
|
|
455 |
|
|
|
379 |
|
| Stock compensation |
|
|
2,407 |
|
|
|
1,992 |
|
| Net operating loss |
|
|
65,351 |
|
|
|
52,588 |
|
| R&D credit |
|
|
9,261 |
|
|
|
9,459 |
|
| Gross deferred tax assets |
|
|
77,967 |
|
|
|
71,663 |
|
| |
|
|
|
|
|
|
|
|
| Investment in subsidiary |
|
|
(1,924 |
) |
|
|
(1,924 |
) |
| Accumulated depreciation and amortization |
|
|
(216 |
) |
|
|
(158 |
) |
| Gross deferred tax liabilities |
|
|
(2,140 |
) |
|
|
(2,082 |
) |
| |
|
|
|
|
|
|
|
|
| Valuation Allowance |
|
|
(75,827 |
) |
|
|
(69,581 |
) |
| |
|
|
|
|
|
|
|
|
| Total Deferred Tax Assets, Net |
|
$ |
— |
|
|
$ |
— |
|
| |
|
|
|
|
|
|
|
|
| Change in Valuation Allowance for the Year Ended |
|
$ |
6,246 |
|
|
$ |
8,702 |
|
|
| The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended December 31, 2025 and 2024: |
The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended December 31, 2025 and 2024:
| |
|
For the Year Ended December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Pre-tax loss |
|
$ |
(26,609 |
) |
|
|
|
|
|
$ |
(23,487 |
) |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Federal tax (benefit) at statutory rate |
|
$ |
(5,588 |
) |
|
|
21.0 |
% |
|
$ |
(4,932 |
) |
|
|
21.0 |
% |
| State tax (benefit), net of federal tax benefit * |
|
|
— |
|
|
|
— |
% |
|
|
2 |
|
|
|
— |
% |
| R&D tax credit from current year |
|
|
384 |
|
|
|
(1.4) |
% |
|
|
(1,911 |
) |
|
|
8.1 |
% |
| Non Deductible Items |
|
|
12 |
|
|
|
(0.1) |
% |
|
|
14 |
|
|
|
(0.1) |
% |
| Foreign Tax Effects ** |
|
|
357 |
|
|
|
(1.3) |
% |
|
|
218 |
|
|
|
(0.9) |
% |
Changes in unrecognized tax benefits
|
|
|
— |
|
|
|
— |
% |
|
|
— |
|
|
|
— |
% |
| Other |
|
|
(4 |
) |
|
|
— |
% |
|
|
(42 |
) |
|
|
0.2 |
% |
| Change in valuation allowance |
|
|
4,839 |
|
|
|
(18.2) |
% |
|
|
6,653 |
|
|
|
(28.3) |
% |
| Total provision for income taxes |
|
$ |
— |
|
|
|
— |
% |
|
|
2 |
|
|
|
— |
% |
* State taxes in California comprised the majority (greater than 50 percent) of the tax effect in this category ** Foreign tax in Switzerland comprised the majority (greater than 50 percent) of the tax effect in this category
|
| As of December 31, 2025, we had federal and apportioned state net operating loss (“NOL”) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): |
As of December 31, 2025, we had federal and apportioned state net operating loss (“NOL”) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):
| |
|
December 31, 2025
|
|
| Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030 |
|
$ |
47,353 |
|
| Post TCJA period federal NOL carry-forward, with no carry-forward limitation |
|
|
206,727 |
|
| Total federal NOL carry-forward |
|
$ |
254,080 |
|
| |
|
|
|
|
| State NOL carry-forward, begin expiring 2030 |
|
$ |
167,590 |
|
| |
|
|
|
|
| Federal R&D tax credit carry-forward, begin expiring in 2036 |
|
$ |
4,428 |
|
| State R&D carry-forward, no expiration date |
|
$ |
9,048 |
|
| Reserve for uncertain income tax positions |
|
|
Nil |
|
|
| The Company has the following activity relating to unrecognized tax benefits (in thousands): |
The Company has the following activity relating to unrecognized tax benefits (in thousands):
| |
|
|
|
|
|
|
| |
|
Year Ended December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Balance at beginning of year |
|
$ |
2,364 |
|
|
$ |
1,692 |
|
| Increases based on tax positions related to the current year |
|
|
299 |
|
|
|
648 |
|
| Increases based on tax positions related to prior years |
|
|
(348 |
) |
|
|
24 |
|
| Reductions based on tax positions related to prior years |
|
|
— |
|
|
|
— |
|
| Balance at end of year |
|
$ |
2,315 |
|
|
$ |
2,364 |
|
|